Novartis' Sandoz Unit Received Positive CHMP Opinion For Breast And Gastric Cancer Biosimilar Trastuzumab
Portfolio Pulse from Charles Gross
Novartis' Sandoz unit has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), recommending marketing authorization for their biosimilar trastuzumab, developed by EirGenix, Inc. The treatment covers HER2-positive breast cancer and metastatic gastric cancers.
September 18, 2023 | 8:43 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novartis' Sandoz unit's positive CHMP opinion for biosimilar trastuzumab could lead to marketing authorization, potentially boosting Novartis' market presence in the cancer treatment sector.
The positive CHMP opinion is a significant step towards marketing authorization for Sandoz's biosimilar trastuzumab. If approved, this could increase Novartis' market share in the cancer treatment sector, potentially leading to increased revenues and a positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100